The matter was reported by a customer complaint.
Presence of glass particulate in an intravenous drug presents a risk for thromboembolism, mechanical blocking of capillaries or arterioles and tissue inflammation. Patients with preexisting conditions of trauma or other conditions that affect the microvascular blood supply are at an increased risk for an adverse event.
No adverse events have yet been reported in association with this issue.
More Articles on Recalls:
Hospira Recalls Propofol Injectable Emulsion, USP
Covidien Recalls Pipeline Embolization Device, Alligator Retrieval Device
What the Increase in Device Recalls Means for Hospitals
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.